A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer

IRB/UVA Tracking #
21211
Contact
Gracie Hockenberry
Contact Email
Contact Phone
1.434.297.7784
Phase
I/II
Primary purpose
Treatment
Cancer PI
Ryan Gentzler
Status
OPEN TO ACCRUAL